Rapport Therapeutics (RAPP) COO sells 2,014 shares for tax withholding

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported an open-market sale of 2,014 shares of common stock at a weighted average price of $28.93 per share. According to the filing, the shares were sold solely to satisfy taxes from the vesting of a previously granted restricted stock unit award and did not represent a discretionary trade. After this transaction, she directly holds 169,914 shares of common stock. The sales occurred in multiple trades at prices ranging from $28.34 to $28.94.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gault Cheryl

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		S(1)		2,014	D	$28.93(2)	169,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.34 to $28.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Troy Ignelzi, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rapport Therapeutics (RAPP) report for Cheryl Gault?

Rapport Therapeutics reported that COO Cheryl Gault sold 2,014 shares of common stock. The sale was an open-market transaction used to cover taxes from vesting restricted stock units, rather than a discretionary decision to reduce her investment.

At what price did Cheryl Gault’s 2,014 RAPP shares sell?

The 2,014 shares sold at a weighted average price of $28.93 per share. The filing notes multiple individual trades executed at prices ranging from $28.34 to $28.94, all on the same transaction date.

Why did Rapport Therapeutics COO sell 2,014 shares of RAPP stock?

The shares were sold to satisfy tax obligations arising from the vesting of a restricted stock unit award. The filing specifies these sales do not represent a discretionary trade by Cheryl Gault, indicating they were tied to tax withholding requirements.

How many Rapport Therapeutics (RAPP) shares does Cheryl Gault hold after the sale?

After the tax-related sale, Cheryl Gault directly holds 169,914 shares of Rapport Therapeutics common stock. This remaining position reflects her continued equity stake in the company following the automatic share sale to cover tax withholding.

What type of security did Cheryl Gault sell in the latest RAPP Form 4?

The transaction involved common stock of Rapport Therapeutics. The Form 4 classifies it as a non-derivative transaction, meaning it related to actual shares rather than options or other derivative securities, and was tied to restricted stock unit vesting.

Was the Rapport Therapeutics (RAPP) insider sale a discretionary trade?

No. The filing explicitly states the sale was to satisfy taxes associated with vesting restricted stock units and that such sales do not represent a discretionary trade by Cheryl Gault, distinguishing it from voluntary buying or selling decisions.